- Aug 31, 2016
- Frostbite Falls, MN
What Is Iboga?
Tabernanthe iboga is a powerful psychedelic from West Africa that has been in use for centuries in traditional healing ceremonies. It can be used in its traditional form from the root bark of the plant (known as iboga), or in the laboratory-isolated form of ibogaine which only contains the central psychoactive substance (known as ibogaine). Today iboga is best known for its miraculous ability to cure or drastically reduce addiction to substances like alcohol, crack cocaine, and heroin in a single treatment. It can also help people overcome addiction to prescription opiates such as morphine, methadone, Vicodin, Percocet, and OxyContin. While this may sound too good to be true, scores of personal testimonies and now clinical research is backing up this claim, and iboga treatment centers are popping up all over the world specializing in treating addiction, post traumatic stress, and mood disorders.
Ibogaine addiction recovery therapy
Ibogaine is an indole alkaloid found in the bark of the root of the African shrub Tabernan. It has strong anti-addictive qualities, including high efficacy in acute opioid withdrawal and addiction. In laymens terms, Ibogaine is a secret tribal hallucinogen that helps you achieve your two most difficult goals.
1) Ibogaine can significantly reduce opiate/opioid withdrawal symptoms in under 24 hours.
2) Ibogaine eliminates the desire for opiates/opioids. Many people who have taken Ibogaine swear that it cured their addiction altogether.
Ibogaine treatment has a mortality rate of 1 in 300, with deaths coming from brachycardia (heart rate slowing way down) and lethal combinations with other drugs. The risks of this treatment should therefore be weighed very carefully, and flood treatment should only be done in a medical setting.
Ibogaine is not currently approved for any medical uses in the U.S. It is used as an alternative medicine treatment for drug addiction in some countries. Its prohibition has slowed scientific research. The use of Ibogaine for drug treatment is now accepted in Canada, Mexico, France, and the UK. In many cases, administration of a therapeutic course of Ibogaine is followed by intensive counseling therapy. Often more than one round of the drug is needed for lasting sobriety.
People with any kind of heart condition should not use ibogaine or iboga in any form.
People who have a bad reaction to the test dose should discontinue ibogaine treatment.
People who have any kind of liver conditions should not do ibogaine or iboga in any form.
People who are on any kind of medications which cause long QT syndrome for which ibogaine will make you temporarily sensitive to should discontinue those meds unless necessary. If those meds are necessary they should not take iboga or ibogaine.
People who have found abnormalities on the EKG, stress test, or CBC/liver panel should not take ibogaine or iboga until if and when those conditions are resolved.
People on MAOIs, SSRIs, or any other psych meds should not take iboga or ibogaine until those meds have cleared the system, we recommend not stopping needed psych meds to take iboga. Some of these medications may potentiate iboga or lead to serotonin syndrome.
If you are currently addicted to benzodiazepines, barbiturates, GHB, GBL, 1,4-BDO, phenibut or alcohol, it is recommended you get through the acute withdrawals before taking ibogaine, as abruptly discontinuing those drugs may lead to seizures. Ibogaine will not eliminate the withdrawals from Gabaergic drugs although it can help with cravings. If you choose to ignore this recommendation then you must tell you treatment provider and your provider must have a Gabaergic drug on hand in case any seizures should happen.
Clinical Guidelines for Ibogaine-Assisted Detoxification
Howard Lotsof (March 1, 1943 to January 31, 2010) was an American scientific researcher who discovered and pioneered the use of ibogaine as a medicine for the treatment of substance addictions. In 1962, at the age of 19, Lotsof was addicted to heroin and accidentally discovered the anti-addictive effects of ibogaine. He attended Fairleigh Dickinson University, and then New York University, graduating with a degree in film in 1976.
Lotsof authored and co-authoring numerous research papers and was awarded a number of patents for the treatment of various chemical dependencies with ibogaine. The first of his patents, issued in 1985, was Rapid Method for Interrupting the Narcotic Addiction Syndrome. The last patent for the use of ibogaine to treat chemical dependence was Rapid Method for Interrupting or Attenuating Poly-Drug Dependency Syndromes. Lotsof was active in promoting the medical use and further research of ibogaine and had an interest in chemical dependence patient advocacy including authoring the Ibogaine Patients' Bill of Rights.
The systematic use of ibogaine was developed first by the Bwiti discipline from where it originated, by the Babongo, Mitsogo and Fang peoples of Gabon and Cameroon, while Western clinical treatment, mostly for the treatment of substance addictions, was pioneered by Lotsof and others. In the 1980s, Lotsof convinced a Belgian company to manufacture Ibogaine in capsule form and performed successful trials in the Netherlands. The use of ibogaine spread across Europe, and was brought to the Americas by Eric Taub in 1992, who had contacted Lotsof in 1989. Lex Kogan later joined Taub and systematized the treatment of ibogaine with centers across the world, and further academic research and trials were conducted by Deborah Mash. As the use of ibogaine spread, its administration has varied widely, with some groups administering it systematically with well developed methods and medical personnel, while many use or administer it haphazardly in a way that many believe is dangerous.
Lotsof was a member of the Board of Directors of the National Alliance of Methadone Advocates and President of the Dora Weiner Foundation. In March of 2009, Lotsof was honored for his discovery of ibogaine's antiaddictive effects during the Sayulita, Mexico ibogaine Provider and Facilitator conference. Some fifty experts from around the world joined to present on ibogaine and associated subjects.
Mr. Lotsof died on January 31, 2010, aged 66, from liver cancer.